Repligen (RGEN) AI Stock Analysis

• Market Cap: $7.01B
• Dividend Yield: N/A
• Average Volume (3M): 841.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: 8.73%
• EPS Growth: -245.82%
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.37
• Shares Outstanding: 56,257,618
• 10 Day Avg. Volume: 728,053
• 30 Day Avg. Volume: 841,954
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 10.85
• Enterprise Value/Gross Profit: 25.40
• Enterprise Value/Ebitda: 58.91
• 1Y Price Target: $177.85
• Price Target Upside: 42.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 61 Neutral
• Price Target: $131.00 ▲(5.17% Upside)

Repligen's overall stock score is driven by strong earnings call performance and technical indicators suggesting a short-term upward trend. However, profitability challenges and valuation concerns weigh down the score. The company's strategic focus on growth and operational efficiency provides a positive outlook, but immediate financial performance improvements are needed to enhance investor confidence.

Positive Factors

Financial Performance

Repligen's 2Q25 financial results showed relatively robust performance, with the company delivering $182.4M in top-line revenue vs. our forecast of $174M.

Market Positioning

Repligen is considered a high-growth story in the attractive bioprocessing market.

Strategic Partnerships

Repligen recently entered into a strategic partnership to develop and integrate the machine learning and modeling workflow of Novasign into Repligen filtration systems.

Negative Factors

Market Sentiment

A recent downturn in gene therapy sentiment due to recent news creates a 1% headwind in the newly raised FY25 guidance.

Profit Margins

Margins missed due to product mix dynamics, creating a 300-basis-point gross margin headwind.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation (RGEN) is a bioprocessing company that specializes in developing and manufacturing high-purity products for the biopharmaceutical industry. The company operates primarily in the life sciences sector, focusing on enabling the production of biologic drugs through its innovative technologies and products. Repligen's core offerings include chromatography resins, filtration systems, and various tools that enhance the efficiency and effectiveness of bioprocessing workflows. Its products are utilized in the production of monoclonal antibodies, therapeutic proteins, and vaccines, catering to a growing demand in the biopharmaceutical market.

How the Company Makes Money

Repligen generates revenue primarily through the sale of its bioprocessing products and technologies. Key revenue streams include the sale of chromatography resins, filtration products, and other consumables used in biomanufacturing processes. The company also derives income from its services related to product development and customer support. Significant partnerships with leading biopharmaceutical companies enhance its market presence and contribute to its earnings by ensuring consistent demand for its products. Additionally, Repligen's focus on innovation and expansion into new markets helps to drive growth and diversify its revenue base.

Repligen Financial Statement Overview

Summary

Repligen's financial performance is mixed, with strong balance sheet indicators like low leverage and a healthy equity ratio. However, profitability challenges are evident with negative net income and EBIT margins, despite positive operational cash flow.

Income Statement

Repligen's revenue shows a marginal growth from the previous year, but has declined from 2022. The gross profit margin for TTM is approximately 54.88%, indicating decent cost management. However, the company is experiencing negative net income and EBIT margins, highlighting profitability challenges. The EBITDA margin is positive at 13.80%, suggesting some operational efficiency.

Balance Sheet

The company's balance sheet is relatively strong with a debt-to-equity ratio of approximately 0.34, indicating low leverage. The equity ratio is around 69.60%, reflecting a healthy balance of equity financing. However, the return on equity is negative due to net losses, which is a concern for investors seeking returns.

Cash Flow

Repligen's cash flow statement shows a decrease in free cash flow compared to the annual report, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative due to the net loss, but operating cash flow remains positive, which indicates underlying operational strength despite profitability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	645.66M	634.44M	632.36M	801.54M	670.53M	366.26M
Gross Profit	275.86M	274.64M	308.83M	455.71M	391.25M	209.63M
EBITDA	118.93M	82.10M	127.77M	246.93M	211.56M	101.62M
Net Income	-25.37M	-25.51M	35.60M	185.96M	128.29M	59.93M
Balance Sheet
Total Assets	2.85B	2.83B	2.83B	2.53B	2.36B	1.90B
Cash, Cash Equivalents and Short-Term Investments	697.23M	757.36M	751.32M	623.76M	603.81M	717.29M
Total Debt	683.70M	686.25M	711.80M	422.96M	366.05M	275.42M
Total Liabilities	866.66M	856.95M	866.34M	620.90M	608.29M	373.74M
Stockholders Equity	1.99B	1.97B	1.96B	1.91B	1.75B	1.53B
Cash Flow
Free Cash Flow	117.60M	142.49M	74.93M	38.74M	47.74M	36.28M
Operating Cash Flow	145.69M	175.39M	113.92M	172.08M	119.02M	62.63M
Investing Cash Flow	-152.13M	-86.38M	-123.28M	-233.24M	-221.17M	-201.38M
Financing Cash Flow	-78.96M	-82.90M	248.96M	-13.34M	961.00K	305.92M

Repligen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 124.56
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Positive. The current price of 124.56 is above the 20-day moving average (MA) of 121.18, above the 50-day MA of 121.49, and below the 200-day MA of 136.82, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 54.93 is Neutral, neither overbought nor oversold. The STOCH value of 50.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	79 Outperform	$5.51B	47.23	8.60%	―	10.14%	0.04%
TFX	73 Outperform	$5.78B	30.77	4.36%	1.04%	1.11%	-23.73%
ATR	71 Outperform	$9.13B	23.91	15.36%	1.30%	1.51%	21.70%
STVN	64 Neutral	$6.59B	45.11	9.55%	0.26%	5.95%	7.73%
RGEN	61 Neutral	$7.01B	―	-0.68%	―	8.73%	-245.82%
BLCO	55 Neutral	$5.31B	―	-4.22%	―	8.81%	40.43%
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%

Repligen Corporate Events

Repligen Appoints Violetta Hughes as Chief Accounting Officer

On September 2, 2025, Repligen Corporation announced the appointment of Violetta Hughes as the new Chief Accounting Officer, effective September 1, 2025. This strategic move aims to enhance the company’s financial reporting infrastructure and compliance with the Sarbanes–Oxley Act. Ms. Hughes, a seasoned finance executive with over 25 years of experience, will replace Jason K. Garland, who will continue as the Chief Financial Officer focusing on corporate strategy and growth. Her extensive background in financial governance and SOX compliance is expected to bring significant improvements to Repligen’s financial transparency and strategic decision-making processes.